Objective:The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian,primary peritoneal or fallopian tube cancers.Methods:Relevant articles were identified from MEDLINE(1993-2010),EMBASE(1980-2010),MEDION,the Cochrane library,Science Citation Index Expanded databases,hand searching of reference lists from primary articles and reviews,conference abstracts and contact with experts in the field.The review included 5 relevant primary studies(1430 women).Data was extracted for study characteristics and quality.Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests.A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies.Results:The frequency of the subgroup analysis of toxicity showed that toxicity action of combination of docetaxel-carboplatin was more severe than that of non docetaxelcarboplatin group(OR = 1.33,95% CI = 1.13-1.56,P = 0.0005),whereas that of clinical responses was equivalent in comparison combination of docetaxel-carboplatin with combination of paclitaxel-carboplatin or docetaxel-cisplatin(OR = 1.0,95% CI = 0.87-1.16,P = 0.95).There were heterogeneity(χ2 = 79.36,P < 0.00001) and inconsistency(83.6%) in toxicity analysis among the trials,while neither heterogeneity(χ2 = 3.21,P = 0.99) nor inconsistency(I2 = 0%) in clinical responses among the trials.Conclusion:The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin.However,the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin. Objective: The aim of this study was to compare the efficacies and safeties of the combination of docetaxelcarboplatin with the combination of non docetaxel-carboplatin as first-line chemotherapy for advanced epithelial ovarian, primary peritoneal or fallopian tube cancers. Methods: Relevant articles were identified from MEDLINE (1993-2010), EMBASE (1980-2010), MEDION, the Cochrane library, Science Citation Index Expanded databases, hand searching of reference lists from primary articles and reviews, conference abstracts and contact with experts in the field. review included 5 relevant primary studies (1430 women). Data was extracted for study characteristics and quality. Bivariate random-effect model metaanalysis was used to estimate diagnostic accuracy of the various index tests. A quantitative meta-analysis was carried out by two reviewers based on the inclusion criteria from all available studies. Results: The frequency of the subgroup analysis of Threiation showed that toxicity action of combinati on of docetaxel-carboplatin was more severe than that of non-docetaxelcarboplatin group (OR = 1.33, 95% CI = 1.13-1.56, P = 0.0005), then that of clinical responses was equivalent in comparison combination of docetaxel- carboplatin with combination of paclitaxel Toxicities were among the trials, while (ε = 1.0,95% CI = 0.87-1.16, P = 0.95). Tumors were heterogeneity (χ2 = 79.36, P <0.00001) and inconsistency (83.6% neither heterogeneity (χ2 = 3.21, P = 0.99) nor inconsistency (I2 = 0%) in clinical responses among the trials. Conlusion: The safety of combination of docetaxel-carboplatin is less than that of combination of paclitaxelcarboplatin or docetaxel-cisplatin. , the clinical responses of combination of docetaxel-carboplatin are comparable with combination of paclitaxel-carboplatin or docetaxel-cisplatin.